See more : Nippon Active Value Fund plc (NAVF.L) Income Statement Analysis – Financial Results
Complete financial analysis of STAAR Surgical Company (STAA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of STAAR Surgical Company, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Ideal Bike Corporation (8933.TWO) Income Statement Analysis – Financial Results
- Izolacja Jarocin Spolka Akcyjna (IZO.WA) Income Statement Analysis – Financial Results
- CAE Inc. (CAE.TO) Income Statement Analysis – Financial Results
- SÜSS MicroTec SE (SESMF) Income Statement Analysis – Financial Results
- Okamura Foods Co., Ltd. (2938.T) Income Statement Analysis – Financial Results
STAAR Surgical Company (STAA)
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 322.42M | 284.39M | 230.47M | 163.46M | 150.19M | 123.95M | 90.61M | 82.43M | 77.12M | 74.99M | 72.22M | 63.78M | 62.77M | 54.96M | 75.35M | 74.89M | 59.36M | 56.28M | 51.30M | 51.69M | 50.46M | 48.25M | 50.24M | 53.99M | 59.00M | 54.20M | 42.50M | 42.20M | 34.70M | 27.40M | 20.10M | 10.20M | 4.30M | 4.50M | 4.50M | 6.80M |
| Cost of Revenue | 69.76M | 61.01M | 51.84M | 45.10M | 38.23M | 32.44M | 26.33M | 24.06M | 24.40M | 26.16M | 21.91M | 19.49M | 20.40M | 19.88M | 33.45M | 34.79M | 30.10M | 29.85M | 27.52M | 25.54M | 22.62M | 24.10M | 28.20M | 22.60M | 18.70M | 14.10M | 6.80M | 7.90M | 6.90M | 4.80M | 3.10M | 2.40M | 2.00M | 2.00M | 7.20M | 8.00M |
| Gross Profit | 252.65M | 223.38M | 178.64M | 118.36M | 111.95M | 91.51M | 64.28M | 58.37M | 52.72M | 48.82M | 50.31M | 44.29M | 42.37M | 35.08M | 41.89M | 40.11M | 29.27M | 26.43M | 23.79M | 26.14M | 27.84M | 24.15M | 22.03M | 31.39M | 40.30M | 40.10M | 35.70M | 34.30M | 27.80M | 22.60M | 17.00M | 7.80M | 2.30M | 2.50M | -2.70M | -1.20M |
| Gross Profit Ratio | 78.36% | 78.55% | 77.51% | 72.41% | 74.54% | 73.83% | 70.94% | 70.81% | 68.36% | 65.11% | 69.67% | 69.44% | 67.50% | 63.82% | 55.60% | 53.55% | 49.30% | 46.97% | 46.36% | 50.58% | 55.17% | 50.05% | 43.86% | 58.14% | 68.31% | 73.99% | 84.00% | 81.28% | 80.12% | 82.48% | 84.58% | 76.47% | 53.49% | 55.56% | -60.00% | -17.65% |
| Research & Development | 44.40M | 35.98M | 33.86M | 31.92M | 25.30M | 22.03M | 19.12M | 20.29M | 14.76M | 12.36M | 6.71M | 6.44M | 5.87M | 5.72M | 5.89M | 7.94M | 6.71M | 7.08M | 5.57M | 6.25M | 5.12M | 4.02M | 3.80M | 4.22M | 4.30M | 3.60M | 3.90M | 4.10M | 3.30M | 2.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 72.32M | 54.74M | 44.14M | 33.91M | 29.31M | 24.29M | 20.67M | 22.25M | 19.60M | 18.48M | 18.81M | 17.79M | 15.99M | 14.08M | 15.71M | 15.73M | 12.95M | 9.34M | 9.34M | 9.34M | 9.34M | 0.00 | 8.75M | 8.59M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 107.83M | 88.86M | 67.29M | 45.76M | 45.49M | 38.60M | 28.13M | 28.48M | 23.70M | 25.88M | 23.89M | 21.28M | 17.73M | 17.18M | 24.26M | 27.05M | 23.72M | 19.51M | 19.51M | 19.51M | 19.51M | 0.00 | 20.04M | 21.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 180.15M | 143.60M | 111.44M | 79.68M | 74.80M | 62.89M | 48.80M | 50.73M | 43.30M | 44.36M | 42.70M | 39.07M | 33.72M | 31.25M | 39.97M | 42.78M | 36.67M | 33.29M | 29.03M | 30.06M | 29.24M | 25.79M | 28.79M | 43.62M | 27.80M | 25.50M | 19.00M | 17.80M | 15.90M | 13.10M | 14.20M | 11.60M | 12.90M | 6.10M | 0.00 | 0.00 |
| Other Expenses | 0.00 | 1.26M | 967.00K | 396.00K | 703.00K | 715.00K | 628.00K | 470.00K | 759.00K | 381.00K | 486.00K | 822.00K | 0.00 | 700.00K | -238.00K | 9.77M | 0.00 | -331.00K | 0.00 | 0.00 | 0.00 | 1.45M | 0.00 | 3.73M | 4.20M | 4.40M | 3.50M | 2.30M | 1.50M | 1.30M | 900.00K | 800.00K | 600.00K | 500.00K | 900.00K | 1.50M |
| Operating Expenses | 224.55M | 179.58M | 145.30M | 111.59M | 100.10M | 84.92M | 67.91M | 71.02M | 58.06M | 56.85M | 49.61M | 45.51M | 39.59M | 37.68M | 45.62M | 60.49M | 43.39M | 40.04M | 34.60M | 36.30M | 34.36M | 31.26M | 32.59M | 51.57M | 36.30M | 33.50M | 26.40M | 24.20M | 20.70M | 17.10M | 15.10M | 12.40M | 13.50M | 6.60M | 900.00K | 1.50M |
| Cost & Expenses | 294.32M | 240.59M | 197.13M | 156.69M | 138.33M | 117.36M | 94.24M | 95.09M | 82.46M | 83.01M | 71.52M | 65.00M | 59.98M | 57.56M | 79.07M | 95.28M | 73.48M | 69.88M | 62.12M | 61.84M | 56.98M | 55.36M | 60.79M | 74.17M | 55.00M | 47.60M | 33.20M | 32.10M | 27.60M | 21.90M | 18.20M | 14.80M | 15.50M | 8.60M | 8.10M | 9.50M |
| Interest Income | 0.00 | 2.45M | 38.00K | 238.00K | 988.00K | 165.00K | 0.00 | 3.00K | 50.00K | 51.00K | 59.00K | 59.00K | 32.00K | 43.00K | 60.00K | 160.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 270.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 2.45M | 0.00 | 0.00 | 0.00 | 165.00K | 0.00 | 115.00K | 128.00K | 154.00K | 170.00K | 291.00K | 523.00K | 896.00K | 1.33M | 901.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.12M | 4.51M | 3.64M | 3.10M | 3.70M | 2.46M | 3.35M | 2.89M | 2.40M | 2.46M | 2.15M | 1.96M | 2.27M | 2.41M | 3.74M | 3.64M | 2.51M | 2.37M | 2.47M | 2.69M | 2.90M | 3.10M | 3.62M | 3.73M | 4.20M | 4.40M | 3.50M | 2.30M | 1.50M | 1.30M | 900.00K | 800.00K | 600.00K | 500.00K | 900.00K | 1.50M |
| EBITDA | 33.22M | 48.31M | 36.98M | 9.86M | 15.55M | 9.06M | -277.00K | -9.66M | -3.08M | -5.14M | 3.44M | 1.75M | 5.49M | -379.00K | 364.00K | -17.13M | -12.19M | -10.88M | -7.32M | -7.34M | -3.62M | -4.01M | -6.93M | -16.45M | 8.20M | 11.00M | 12.80M | 12.40M | 8.60M | 6.80M | 2.80M | -3.80M | -10.60M | -3.60M | -2.70M | -1.20M |
| EBITDA Ratio | 10.30% | 17.59% | 17.33% | 5.51% | 10.70% | 7.98% | -1.21% | -11.27% | -2.76% | -6.85% | 4.70% | 2.54% | 8.10% | -0.28% | 0.10% | -22.15% | -18.54% | -20.45% | -17.06% | -14.63% | -6.12% | -4.81% | 1.54% | -21.19% | 13.39% | 19.00% | 23.06% | 27.96% | 23.05% | 21.90% | 10.45% | -63.73% | -244.19% | -313.33% | -60.00% | -19.12% |
| Operating Income | 28.10M | 43.80M | 33.34M | 6.77M | 11.85M | 6.60M | -3.63M | -12.66M | -5.34M | -8.03M | 700.00K | -1.22M | 2.78M | -2.60M | -3.73M | -20.39M | -14.12M | -13.60M | -10.81M | -10.16M | -6.53M | -7.11M | -17.79M | -20.18M | 4.00M | 6.60M | 9.30M | 10.10M | 7.10M | 5.50M | 1.90M | -4.60M | -11.20M | -4.10M | -3.60M | -2.70M |
| Operating Income Ratio | 8.71% | 15.40% | 14.47% | 4.14% | 7.89% | 5.32% | -4.01% | -15.35% | -6.92% | -10.70% | 0.97% | -1.91% | 4.43% | -4.73% | -4.95% | -27.22% | -23.78% | -24.17% | -21.07% | -19.65% | -12.93% | -14.74% | -35.40% | -37.38% | 6.78% | 12.18% | 21.88% | 23.93% | 20.46% | 20.07% | 9.45% | -45.10% | -260.47% | -91.11% | -80.00% | -39.71% |
| Total Other Income/Expenses | 5.60M | 1.75M | -2.04M | 1.50M | 1.17M | 44.00K | 1.34M | 211.00K | -268.00K | -618.00K | 414.00K | 701.00K | -79.00K | -1.08M | -741.00K | -1.29M | -1.04M | 95.00K | 854.00K | -88.00K | -705.00K | -1.01M | 2.99M | -5.30M | -900.00K | -500.00K | 2.40M | 100.00K | 300.00K | 600.00K | 700.00K | 2.70M | -100.00K | 10.00M | 0.00 | -800.00K |
| Income Before Tax | 33.70M | 45.80M | 31.30M | 8.27M | 13.03M | 6.64M | -2.30M | -12.44M | -5.61M | -8.65M | 1.11M | -519.00K | 2.70M | -3.68M | -4.71M | -21.67M | -15.16M | -13.51M | -9.96M | -10.25M | -7.16M | -8.12M | -18.24M | -25.48M | 3.10M | 6.10M | 11.70M | 10.20M | 7.40M | 6.10M | 2.60M | -1.90M | -11.30M | 5.90M | 0.00 | -3.50M |
| Income Before Tax Ratio | 10.45% | 16.11% | 13.58% | 5.06% | 8.67% | 5.36% | -2.53% | -15.10% | -7.27% | -11.53% | 1.54% | -0.81% | 4.31% | -6.70% | -6.25% | -28.94% | -25.53% | -24.00% | -19.41% | -19.82% | -14.19% | -16.84% | -36.31% | -47.20% | 5.25% | 11.25% | 27.53% | 24.17% | 21.33% | 22.26% | 12.94% | -18.63% | -262.79% | 131.11% | 0.00% | -51.47% |
| Income Tax Expense | 12.35M | 6.80M | 6.80M | 2.35M | -1.02M | 1.67M | -157.00K | -315.00K | 928.00K | -253.00K | 716.00K | 1.24M | 1.36M | 432.00K | 1.49M | 1.52M | 843.00K | 1.54M | 1.24M | 1.06M | 1.13M | 8.96M | -3.55M | -6.58M | 900.00K | 2.00M | 4.30M | 3.30M | -100.00K | -2.20M | 100.00K | 500.00K | 100.00K | 2.60M | 800.00K | 200.00K |
| Net Income | 21.35M | 39.67M | 27.51M | 5.91M | 14.05M | 4.97M | -2.14M | -12.13M | -6.53M | -8.39M | 398.00K | -1.76M | 1.35M | 53.00K | -6.20M | -23.20M | -16.00M | -15.04M | -11.18M | -11.33M | -8.36M | -17.16M | -14.83M | -18.90M | 2.20M | 2.40M | 7.40M | 6.90M | 7.50M | 8.30M | 2.50M | -5.10M | -11.30M | 3.50M | -4.40M | -3.80M |
| Net Income Ratio | 6.62% | 13.95% | 11.94% | 3.62% | 9.35% | 4.01% | -2.36% | -14.71% | -8.47% | -11.19% | 0.55% | -2.76% | 2.15% | 0.10% | -8.23% | -30.97% | -26.95% | -26.73% | -21.78% | -21.93% | -16.56% | -35.56% | -29.53% | -35.01% | 3.73% | 4.43% | 17.41% | 16.35% | 21.61% | 30.29% | 12.44% | -50.00% | -262.79% | 77.78% | -97.78% | -55.88% |
| EPS | 0.44 | 0.83 | 0.52 | 0.13 | 0.32 | 0.11 | -0.05 | -0.30 | -0.17 | -0.22 | 0.01 | -0.05 | 0.04 | 0.00 | -0.19 | -0.79 | -0.57 | -0.60 | -0.47 | -0.58 | -0.47 | -1.00 | -0.87 | -1.23 | 0.15 | 0.18 | 0.57 | 0.50 | 0.55 | 0.84 | 0.21 | -0.50 | -1.22 | 1.44 | -1.59 | -1.52 |
| EPS Diluted | 0.43 | 0.80 | 0.50 | 0.12 | 0.30 | 0.11 | -0.05 | -0.30 | -0.17 | -0.22 | 0.01 | -0.05 | 0.04 | 0.00 | -0.19 | -0.79 | -0.57 | -0.60 | -0.47 | -0.58 | -0.47 | -1.00 | -0.87 | -1.23 | 0.15 | 0.17 | 0.53 | 0.50 | 0.55 | 0.80 | 0.20 | -0.50 | -1.22 | 1.44 | -1.59 | -1.52 |
| Weighted Avg Shares Out | 48.52M | 47.99M | 47.21M | 45.61M | 44.49M | 45.16M | 41.00M | 40.33M | 38.43M | 38.09M | 36.71M | 35.26M | 35.43M | 34.83M | 32.50M | 29.47M | 28.12M | 25.23M | 23.70M | 19.60M | 17.70M | 17.14M | 17.00M | 15.37M | 14.67M | 13.33M | 12.98M | 13.80M | 13.64M | 9.88M | 11.90M | 10.20M | 9.29M | 4.06M | 2.76M | 2.50M |
| Weighted Avg Shares Out (Dil) | 49.43M | 49.38M | 49.46M | 47.95M | 46.90M | 45.26M | 41.00M | 40.33M | 39.26M | 38.09M | 38.61M | 36.25M | 36.88M | 34.83M | 32.50M | 29.47M | 28.12M | 25.23M | 23.70M | 19.60M | 17.70M | 17.16M | 17.00M | 15.37M | 14.67M | 14.12M | 13.96M | 13.80M | 13.64M | 10.38M | 12.50M | 10.20M | 9.29M | 4.06M | 2.76M | 2.50M |
EVO ICL Sponsors Jonas Brothers’ The Tour
LAKE FOREST, Calif.--(BUSINESS WIRE)--EVO ICL, the vision correction procedure that works in harmony with your natural eye, provides sharp, clear vision day or night and does not cause contact lens induced dry eye or dry eye syndrome, announced today sponsorship...
STAAR Surgical Company (STAA) Q1 2023 Earnings Call Transcript
STAAR Surgical Company (NASDAQ:STAA ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Brian Moore - VP of Investor, Media Relations and Corporate Development Tom Frinzi - President and CEO Patrick Williams - CFO Conference...
STAAR Surgical Reports First Quarter 2023 Results
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Overview Net Sales of $73.5...
STAAR Surgical Reports First Quarter 2023 Results
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Overview Net Sales of $73.5...
STAAR Surgical to Report First Quarter Results on May 3, 2023
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the first quarter ended March 31, 2023 on Wednesday, May 3,...
STAAR Surgical Names Warren Foust Chief Operating Officer; Magda Michna, Ph.D., Chief Clinical, Regulatory and Medical Affairs Officer
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced Warren Foust has been named Chief Operating Officer and Magda Michna, Ph.D., has been named Chief Clinical, Regulatory...
STAAR Surgical Names Warren Foust Chief Operating Officer; Magda Michna, Ph.D., Chief Clinical, Regulatory and Medical Affairs Officer
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced Warren Foust has been named Chief Operating Officer and Magda Michna, Ph.D., has been named Chief Clinical, Regulatory...
STAAR Surgical Company (STAA) Q4 2022 Earnings Call Transcript
STAAR Surgical Company (NASDAQ:STAA ) Q4 2022 Earnings Conference Call February 21, 2023 4:30 PM ET Company Participants Brian Moore - Vice President of Investor, Media Relations & Corporate Development Tom Frinzi - President, Chief Executive Officer & Chairman Patrick...
Staar Surgical (STAA) Lags Q4 Earnings and Revenue Estimates
Staar Surgical (STAA) delivered earnings and revenue surprises of -6.67% and 0.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2022 Results
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the fourth quarter and fiscal year ended December 30, 2022. Fourth Quarter 2022 Overview Net...
Source: https://incomestatements.info
Category: Stock Reports